---

---

approved   entities : Abbvie inc.   

save search

---

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
Published: 2024-03-22 (Crawled : 19:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| Email alert Add to watchlist
elahere drug approval food cancer grants

---

Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| 4.69% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | News | $138.24 -4.19% 800 |

Health Technology

| 3.09% | O: 3.41% H: 0.0% C: -2.45%
VTRS A | $11.25 1.17% 1.16% 4.7M |

Health Technology

| -5.84% | O: -0.08% H: 3.47% C: -0.25%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -13.61% | O: -2.04% H: 0.19% C: -1.97%
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| 1.3% | O: 4.04% H: 1.57% C: -3.02%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 0.15% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -9.47% | O: 1.75% H: 0.0% C: 0.0%
PBYI | $5.01 0.4% 0.4% 290K |

Health Technology

| 8.5% | O: -0.1% H: 2.31% C: -1.26%
AZN | News | $68.56 0.29% 0.29% 4.7M |

Health Technology

| 1.58% | O: 0.82% H: 0.12% C: -1.64%
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| -15.79% | O: 0.44% H: 0.2% C: -0.55%
drug breast expected cancer pipeline therapeutics growth market

---

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
Published: 2023-08-17 (Crawled : 06:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 8.32% | O: -0.87% H: 0.49% C: -0.75%
aquipta abbvie approval treatment migraine

---

Global Nasal Implants Market to Witness Impressive Growth with Rising Demand for Aesthetic Surgeries and Favorable Government Approvals
Published: 2023-08-01 (Crawled : 00:00) - prnewswire.com
SYK | $325.43 -0.62% 0.0% 1.8M |

Health Technology

| 19.65% | O: -0.98% H: 0.6% C: -1.27%
MDT | $79.48 0.37% -0.29% 6.7M |

Health Technology

| -9.42% | O: -0.25% H: 0.3% C: -1.86%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -13.05% | O: 1.28% H: 0.0% C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 9.9% | O: -1.44% H: 1.66% C: 0.86%
SIEN | $0.174 0.69% 3.4M |

Health Technology

| -94.29% | O: 2.13% H: 0.52% C: -5.22%
IART | $28.68 -9.33% -10.29% 2.9M |

Health Technology

| -30.11% | O: -1.68% H: 0.28% C: -0.04%
aesthetic favorable global growth market

---

EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2023-05-19 (Crawled : 17:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 15.14% | O: 0.29% H: 1.35% C: 0.87%
fda antibody approved

---

EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2023-05-19 (Crawled : 16:00) - globenewswire.com
GNMSF | $290.38 3.83% 220 |

Health Technology

| -31.43% | O: 0.61% H: 1.26% C: 1.24%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 15.14% | O: 0.29% H: 1.35% C: 0.87%
GMAB | $28.72 1.38% 1.36% 360K |

Health Technology

| -29.87% | O: 0.54% H: 2.0% C: 1.81%
drug antibody approved food

---

U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
Published: 2023-05-18 (Crawled : 23:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 15.21% | O: -0.52% H: 0.67% C: 0.58%
rinvoq fda disease active

---

U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
Published: 2023-04-18 (Crawled : 08:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 2.47% | O: -0.11% H: 0.14% C: -0.88%
qulipta fda migraine

---

U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
Published: 2023-04-17 (Crawled : 00:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 2.47% | O: -0.11% H: 0.14% C: -0.88%
qulipta fda migraine

---

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
Published: 2023-04-17 (Crawled : 07:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 2.21% | O: 0.2% H: 0.17% C: -0.46%
rinvoq disease abbvie active approval treatment

---

Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio
Published: 2023-03-10 (Crawled : 23:00) - prnewswire.com
AMGN | $269.03 2.39% 2.33% 3.4M |

Health Technology

| Email alert Add to watchlist
CTIC | $9.09 0.05% 11M |

Health Technology

| Email alert Add to watchlist
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| Email alert Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| Email alert Add to watchlist
NVSEF | $93.6375 6.88% 82K |

Health Technology

| Email alert Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| Email alert Add to watchlist
TEVJF | News | $12.37 -24.22% 380 |

Health Technology

| Email alert Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| Email alert Add to watchlist
ADCT | $4.72 -0.84% 0.0% 320K |

Health Technology

| Email alert Add to watchlist
approval therapeutics growth market

---

U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
Published: 2022-12-16 (Crawled : 00:20) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| Email alert Add to watchlist
vraylar treatment fda major depressive disorder

---

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
Published: 2022-11-23 (Crawled : 08:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 3.36% | O: 0.1% H: 0.62% C: -0.35%
skyrizi treatment disease active approval

---

U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
Published: 2022-11-21 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 6.57% | O: 0.27% H: 2.08% C: 1.1%
cd20 duobody treatment fda application license review

---

RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval
Published: 2022-10-21 (Crawled : 21:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| Email alert Add to watchlist
rinvoq fda approval

---

FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
Published: 2022-08-03 (Crawled : 13:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 16.94% | O: 0.32% H: 0.0% C: 0.0%
derm fda

---

Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio
Published: 2022-08-03 (Crawled : 04:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510 |

Health Technology

| -3.23% | O: -1.8% H: 0.2% C: 0.0%
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -8.03% | O: -2.6% H: 0.0% C: -0.76%
NPCE S | $13.78 -1.57% -1.6% 96K |

Manufacturing

| 138.3% | O: 0.52% H: 3.71% C: -2.93%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| 9.43% | O: 0.11% H: 0.31% C: -0.34%
GSK | News | $39.75 1.22% 0.0% 1.6M |

Health Technology

| -3.84% | O: -0.29% H: 0.24% C: -0.58%
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 16.94% | O: 0.32% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -8.18% | O: -0.17% H: 0.12% C: -1.29%
BIIB | $194.39 2.03% 1.99% 1.6M |

Health Technology

| -6.69% | O: 0.41% H: 3.35% C: 1.71%
ACAD | $16.82 -1.47% -1.49% 3.5M |

Health Technology

| 14.66% | O: 2.47% H: 2.8% C: -2.67%
approval therapeutics growth market

---

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
Published: 2022-07-29 (Crawled : 07:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 9.04% | O: -4.04% H: 0.0% C: 0.0%
rinvoq treatment active approved

---

European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis
Published: 2022-07-26 (Crawled : 07:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 11.03% | O: 1.61% H: 0.0% C: 0.0%
rinvoq treatment ulcerative colitis

---

CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
Published: 2022-06-27 (Crawled : 07:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| 9.57% | O: 1.55% H: 0.0% C: 0.0%
rinvoq treatment active chmp approval

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---